TRACON Pharmaceuticals Announces Poster Presentations at the 2021 ASCO Virtual Annual Meeting
TRACON Pharmaceuticals (NASDAQ: TCON) announced two abstracts for the American Society of Clinical Oncology (ASCO) 2021 annual meeting from June 4-8, 2021. The first abstract covers the ENVASARC pivotal trial of Envafolimab, targeting advanced or metastatic undifferentiated pleomorphic sarcoma or myxofibrosarcoma. The second discusses the preliminary data of TJ004309, a CD73 antibody combined with atezolizumab in advanced cancer. Envafolimab shows promising response rates in prior trials, being compared favorably against established therapies.
- Presentation of two significant abstracts at ASCO 2021, highlighting innovative therapies.
- Envafolimab shows a confirmed objective response rate (ORR) of 32% in MSI-H/dMMR colorectal cancer patients, comparable to leading therapies like Opdivo and Keytruda.
- None.
SAN DIEGO, May 20, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., today announced the presentation of two abstracts at the upcoming American Society of Clinical Oncology (ASCO) 2021 annual meeting, being held virtually June 4-8, 2021.
| Poster Presentation: | ||
| Abstract Title: | ENVASARC: A Pivotal Trial of Envafolimab, and Envafolimab in Combination with Ipilimumab, in Patients with Advanced or Metastatic Undifferentiated Pleomorphic Sarcoma or Myxofibrosarcoma who have Progressed on Prior Chemotherapy | |
| Abstract Number: | TPS11581 | |
| Poster Session: | Sarcoma | |
| Session Start: | June 4, 2021 9:00AM EDT | |
| Poster Discussion Session: | ||
| Abstract Title: | Preliminary safety, pharmacokinetics (PK), pharmacodynamics (PD) and clinical efficacy of Uliledlimab (TJ004309), a differentiated CD73 antibody, in combination with atezolizumab in patients with advanced cancer | |
| Abstract Number: | 2511 | |
| Poster Session: | Development Therapeutics-Immunotherapy | |
| Session Start: | June 4, 2021 9:00AM EDT | |
The posters will be available on the publications page of the company’s website following presentation.
About Envafolimab
Envafolimab (KN035), a novel, single-domain antibody against PD-L1, is the first subcutaneously injected PD-(L)1 inhibitor to be studied in pivotal trials. Envafolimab is currently being studied in the ENVASARC Phase 2 pivotal trial in the U.S. sponsored by TRACON, has been studied in a completed Phase 2 pivotal trial as a single agent in MSI-H/dMMR advanced solid tumor patients in China and is being studied in an ongoing Phase 3 pivotal trial in combination with gemcitabine and oxaliplatin in advanced biliary tract cancer patients in China, with both Chinese trials sponsored by 3D Medicines. TRACON’s partners Alphamab Oncology and 3D Medicines submitted an NDA to the NMPA in China for envafolimab in MSI-H/dMMR cancer that was accepted for review in December 2020 and granted priority review in January 2021. In the Phase 2 MSI-H/dMMR advanced solid tumor trial, the confirmed objective response rate (ORR) by blinded independent central review in MSI-H/dMMR colorectal cancer (CRC) patients treated with envafolimab who failed a fluoropyrimidine, oxaliplatin and irinotecan was
About ENVASARC (NCT04480502)
The ENVASARC pivotal trial is a multi-center, open label, randomized, non-comparative, parallel cohort study at approximately 25 top cancer centers in the United States that began dosing in December 2020. TRACON expects the trial to enroll 160 patients with UPS or MFS who have progressed following one or two lines of prior treatment and have not received an immune checkpoint inhibitor, with 80 patients enrolled into cohort A of treatment with single agent envafolimab and 80 patients enrolled in cohort B of treatment with envafolimab and Yervoy. The primary endpoint is ORR by blinded independent central review with duration of response a key secondary endpoint.
About TJ004309
TJ004309 is a novel, humanized antibody against CD73, an ecto-enzyme expressed on stromal cells and tumors that converts extracellular adenosine monophosphate (AMP) to adenosine, which is highly immunosuppressive. TJ004309 is currently being studied in an ongoing Phase 1 trial to assess safety and preliminary efficacy as a single agent and when combined with the PD-L1 checkpoint inhibitor Tecentriq in patients with advanced solid tumors.
About TRACON
TRACON develops targeted therapies for cancer utilizing a capital efficient, CRO independent, product development platform. The Company’s clinical-stage pipeline includes: Envafolimab, a PD-L1 single-domain antibody given by rapid subcutaneous injection that is being studied in the pivotal ENVASARC trial for sarcoma; TRC102, a Phase 2 small molecule drug candidate for the treatment of lung cancer; and TJ004309, a CD73 antibody in Phase 1 development for the treatment of advanced solid tumors. TRACON is actively seeking additional corporate partnerships whereby it leads U.S. regulatory and clinical development and shares in the cost and risk of clinical development and leads U.S. commercialization. In these partnerships TRACON believes it can serve as a solution for companies without clinical and commercial capabilities in the U.S. To learn more about TRACON and its product pipeline, visit TRACON's website at www.traconpharma.com.
| Company Contact: | Investor Contact: |
| Mark Wiggins | Brian Ritchie |
| Chief Business Officer | LifeSci Advisors LLC |
| 858-251-3492 | 212-915-2578 |
| mwiggins@traconpharma.com | britchie@lifesciadvisors.com |
FAQ
What will TRACON Pharmaceuticals present at ASCO 2021?
What is the focus of the ENVASARC trial by TRACON Pharmaceuticals?
What are the response rates of Envafolimab compared to other therapies?
When is the ASCO 2021 annual meeting taking place?
